Last reviewed · How we verify
NCT05933447
Thorough QT Study to Evaluate the Effect of Rodatristat Ethyl, Rodatristat and Its Major Metabolites on the Heart
Phase 1 trial testing Rodatristat Ethyl in Healthy in 27 participants. Completed in 28 July 2023.
28 July 2023
Quick facts
| Lead sponsor | Altavant Sciences GmbH |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 27 |
| Start date | 12 May 2023 |
| Primary completion | 28 July 2023 |
| Estimated completion | 28 July 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Rodatristat Ethyl — full drug profile →
- Moxifloxacin (moxifloxacin) — full drug profile →
- Placebo for Rodatristat — full drug profile →
- Placebo for Moxifloxacin — full drug profile →
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Altavant Sciences GmbH — full company profile →
Who can join
Adults 18 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate whether Rodatristat Ethyl prolongs the QTc interval when orally administered to healthy volunteers.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05933447
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rodatristat Ethyl
Trials testing the same drug.
- NCT05684640 — A Single and Multiple Dose of Rodatristat Ethyl in Healthy Adult Subjects to Evaluate the Effect of Food and Safety · Phase 1 · completed
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Altavant Sciences GmbH trials
Trials by the same sponsor.
- NCT05684640 — A Single and Multiple Dose of Rodatristat Ethyl in Healthy Adult Subjects to Evaluate the Effect of Food and Safety · Phase 1 · completed
- NCT05065359 — Multiple-Ascending Dose in Japanese Patients Bridging Study · Phase 1 · completed
- NCT05006118 — Pharmacokinetics and Excretion of Oral [14C]-Rodatristat Ethyl · Phase 1 · completed
- NCT04712669 — A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE) · Phase 2 · completed
- NCT03924154 — A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1) · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05933447 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Altavant Sciences GmbH
- Last refreshed: 3 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05933447.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing